MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease affecting approximately 1,300 newborns in North America each year.

Montreal, QC – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today they have signed a memorandum of understanding (MOU) with Moderna Canada to support biomanufacturing training for employees at Moderna’s new vaccine manufacturing facility in Laval, Quebec.

MONTREAL, February 1, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell therapies, announced today a publication in the journal Blood that further elucidates the UM171 mechanism of action and highlights the potential for UM171 to result in the efficient expansion of stem cells with preserved function for therapeutic use.

While the entire planet was on pause, or at least in slow motion, during the all too drawn-out period of the pandemic, the life sciences sector was in a flurry of activity.

Laval, Québec & West Palm Beach, Florida, October 13, 2023 — BIOQuébec and BioFlorida, preeminent life sciences associations from Québec and Florida, are proud to announce the signing of a Memorandum of Understanding (MOU). This agreement is set to intensify collaboration and bolster industry growth in of both regions.

Boston (Massachussetts), June 5, 2023 – At the 2023 BIO International Convention BIOQuébec and MassBio agreed to extend their existing memorandum of cooperation and collaboration for a 3-year period. This agreement, originally initiated in 2017 and renewed in 2019 at the same conference aims to facilitate business ties between their respective members and support the market development initiatives of both Québec and Massachusetts-based biotechnology sector companies.

Laval, April 13, 2023 – BIOQuébec’s board of directors is proud to announce that Benoit Larose has been named its executive director, effective May 1, 2023.

A CRO, or contract research organization, is a company that provides, on a contractual basis, services in the biomedical research field. Given their crucial role in the development of new treatments and technologies, as well as their economic importance, BIOQuébec and CATALIS, with financial support from the Ministry of Economy and Innovation, conducted a study of Quebec CROs to chart the sector’s impact and measure its growth, strengths, and needs.

BIOQuébec commissioned The JBL Group to produce a comprehensive account of the situation by first, rigorously documenting the Quebec healthcare system’s recommendation process for Quebec-based innovations and secondly, to develop, with industry partners, public policy proposals that would support the Quebec biopharmaceutical industry’s innovations and development. BIOQuébec’s review was prompted by a widespread perception among many members that Quebec-based drugs and biopharmaceutical industry products were unfavourably considered by the Quebec health and social services network.

On December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.